Aticaprant Oral Tablet Formulation for MDD Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for major depressive disorder (MDD) and anhedonia, particularly for patients who have had inadequate responses to first-line antidepressants, are inadequate, with many patients failing to achieve full remission.
Innovation Solution
A pharmaceutical composition in the form of an oral tablet containing 10 mg aticaprant with a specific intragranular and extragranular phase, comprising microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, silica, and silicified microcrystalline cellulose, which provides a targeted pharmacokinetic profile and dissolution profile for effective treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antidepressant treatments are used for patients with major depressive disorder and anhedonia, then initial treatment can be provided, but most patients fail to achieve full remission and require multiple treatment switches
Solution Approach 1:
The patent introduces aticaprant, a kappa opioid receptor antagonist, which represents a fundamental change in the pharmacological parameter class being targeted. Instead of using conventional antidepressants that primarily target serotonin and norepinephrine systems, this compound targets the kappa opioid receptor pathway, thereby achieving treatment efficacy in patients who have failed multiple conventional antidepressant treatments
Solution Approach 2:
The patent employs aticaprant as an intermediary substance that blocks kappa opioid receptor activation by endogenous ligands such as dynorphin. This intermediary action prevents the negative signaling cascade that contributes to anhedonia and depressive symptoms, providing a novel mechanism of action that bypasses the limitations of conventional antidepressant pathways
2Adaptability or versatility
If multiple antidepressant treatments are tried sequentially, then more treatment options are explored, but treatment complexity and time to remission increase significantly
Solution Approach 1:
The patent segments the treatment approach by identifying and targeting a specific pathological mechanism (kappa opioid receptor overactivation) that is distinct from conventional antidepressant mechanisms. This segmentation allows for a focused monotherapy approach with aticaprant rather than requiring complex combination therapies or sequential trials of multiple drug classes
Solution Approach 2:
Aticaprant demonstrates universality by addressing multiple symptoms of major depressive disorder and anhedonia through a single mechanism of action. The kappa opioid receptor antagonism provides broad therapeutic effects including improvement in mood, anhedonia, and stress response, eliminating the need for multiple specialized treatments
3Quantity of substance
If higher doses of aticaprant are administered, then pharmacokinetic exposure increases, but dissolution rate and absorption may be affected
Solution Approach 1:
The patent utilizes solid dispersion technology and amorphous formulation approaches to change the physical state and dissolution parameters of aticaprant. By transforming the crystalline solid into an amorphous or poorly crystalline state within a matrix carrier, the dissolution rate is dramatically enhanced, allowing for complete dissolution and optimal absorption even at low doses of 10 mg
Solution Approach 2:
The patent employs composite material formulations where aticaprant is dispersed within a matrix of hydrophilic carriers such as hydroxypropyl cellulose, polyvinylpyrrolidone, or sugars. This composite approach creates a formulation system where the matrix material facilitates rapid dissolution and release of the active ingredient, optimizing the relationship between dose quantity and dissolution speed
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.